The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Feasibility and conduct of INSIGhT, a platform trial of patients with glioblastoma using Bayesian adaptive randomization.
 
Eudocia Quant Lee
Honoraria - Continuum (American Academy of Neurology); Medlink
Consulting or Advisory Role - Medscape
Patents, Royalties, Other Intellectual Property - Royalties from Wolter Kluwer for Up to Date, Inc
 
Lorenzo Trippa
Consulting or Advisory Role - Galera Therapeutics
Research Funding - Candel Therapeutics (Inst)
 
Geoffrey Fell
No Relationships to Disclose
 
Rifaquat Rahman
Research Funding - Bristol-Myers Squibb (Inst)
 
Isabel Arrillaga-Romany
Honoraria - Merck
Consulting or Advisory Role - Agios; Boehringer Ingelheim; Boehringer Ingelheim; FORMA Therapeutics; Insys Therapeutics; Karus Therapeutics
Research Funding - Astex Pharmaceuticals
 
Jan Drappatz
Leadership - Elsevier
Stock and Other Ownership Interests - Biogen; Bristol-Myers Squibb; Exelixis; Gilead Sciences; GlaxoSmithKline; Pfizer
Honoraria - Agios; Elsevier; Novocure; UpToDate
Consulting or Advisory Role - Agios; Immunomic Therapeutics; Novocure; Oncorus
Patents, Royalties, Other Intellectual Property - uptodate
 
Mary Roberta Welch
Research Funding - Boston Biomedical; Inovio Pharmaceuticals
Travel, Accommodations, Expenses - Boston Biomedical; Inovio Pharmaceuticals
 
Evanthia Galanis
Consulting or Advisory Role - Agios (Inst); Gradalis; Karyopharm Therapeutics (Inst); MedImmune (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); MedImmune (Inst); TRACON Pharma (Inst)
 
Manmeet Singh Ahluwalia
Stock and Other Ownership Interests - CytoDyn; doctible; MedInnovate Advisors LLC; MimiVax
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology
Consulting or Advisory Role - Apollomics; Bayer; Celularity; GlaxoSmithKline; InSightec; Janssen; KIYATEC; Novocure; Nuvation Bio; Prelude Therapeutics; SDP Oncology; ViewRay; Voyager Therapeutics; Xoft
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst)
 
Howard Colman
Consulting or Advisory Role - Abbvie; Adastra Pharmaceuticals; Adastra Pharmaceuticals; Bayer; Best Doctors, Inc; FORMA Therapeutics; Karyopharm Therapeutics; Newlink Genetics; Orbus Therapeutics; Private Health
Research Funding - Abbvie (Inst); Array BioPharma (Inst); Bayer; BeiGene (Inst); Bristol-Myers Squibb; DNAtrix (Inst); FORMA Therapeutics (Inst); Global Coalition for Adaptive Research (Inst); Kadmon (Inst); Merck (Inst); Newlink Genetics (Inst); Nuvation Bio; Orbus Therapeutics (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; FORMA Therapeutics; Karyopharm Therapeutics; Orbus Therapeutics
 
Louis B. Nabors
Consulting or Advisory Role - Chimerix
Patents, Royalties, Other Intellectual Property - Development of novel inhibitors to HuR through NCI funded peer reviewed research.
Other Relationship - cns pharmaceuticals; University of Pennsylvania
 
Jaroslaw T. Hepel
No Relationships to Disclose
 
David Schiff
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Orbus Therapeutics; PRA
Research Funding - Bayer (Inst)
 
Thomas Joseph Kaley
No Relationships to Disclose
 
Christine Lu-Emerson
Consulting or Advisory Role - Janssen
Travel, Accommodations, Expenses - Janssen
 
E. Antonio Chiocca
Stock and Other Ownership Interests - DNAtrix; Immunomic Therapeutics; Seneca Therapeutics
Honoraria - GlaxoSmithKline; Merck
Consulting or Advisory Role - Advantagene; DNAtrix; InSightec; Merck; Sangamo Therapeutics; Voyager Therapeutics
Research Funding - Amgen; Newlink Genetics
Patents, Royalties, Other Intellectual Property - Patents related to oncolytic virus technology, gene therapy, microRNA, exosome, antibodies
 
David A. Reardon
Honoraria - Advantagene; Agenus; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Deciphera; DelMar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kintara Therapeutics; KIYATEC; Medicenna; Merck; Merck KGaA; NEUVOGEN; Novocure; Oncorus; Regeneron; Sumitono Dainippon Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Vivacitas Oncology; Y-mAbs Therapeutics
Consulting or Advisory Role - Advantagene; Agenus; Agios; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Delmar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Kintara Therapeutics; Kiyatec; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical; Vivacitas Oncology
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Enterome (Inst); Incyte (Inst); Omniox
 
Keith L. Ligon
No Relationships to Disclose
 
Brian Michael Alexander
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Roche
Research Funding - Celgene (Inst); Lilly (Inst); Puma Biotechnology (Inst)
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Black Diamond Therapeutics; Blue Earth Diagnostics; Boston Pharmaceuticals; Celularity; Chimerix; Day One Biopharmaceuticals; ElevateBio; Imvax; Integral Health; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Novocure; Nuvation Bio; Prelude Therapeutics; QED Therapeutics; Sapience Therapeutics; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Research Funding - Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Chimerix (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)